Pacira Biosciences, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6951271005
USD
23.98
-0.09 (-0.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Pacira Biosciences, Inc. stock-summary
stock-summary
Pacira Biosciences, Inc.
Pharmaceuticals & Biotechnology
Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
Company Coordinates stock-summary
Company Details
5 Sylvan Way Ste 300 , PARSIPPANY NJ : 07054-3813
stock-summary
Tel: 1 973 25435601 973 4514030
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 96 Schemes (62.02%)

Foreign Institutions

Held by 123 Foreign Institutions (14.53%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. David Stack
Chairman of the Board, Chief Executive Officer
Mr. Paul Hastings
Lead Independent Director
Gov. Christopher Christie
Director
Ms. Laura Brege
Independent Director
Dr. Mark Froimson
Independent Director
Dr. Yvonne Greenstreet
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
181 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,202 Million (Small Cap)

stock-summary
P/E

19.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.19

stock-summary
Return on Equity

5.05%

stock-summary
Price to Book

1.59